SageView Advisory Group
PTGX icon

SageView Advisory Group’s Protagonist Therapeutics PTGX Stock Holding History

SageView Advisory Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-106
Closed -$9.26K – 1963
2025
Q4 		$9.26K Buy
+106
New +$8.68K ﹤0.01% 1745

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

SageView Advisory Group's PTGX Position: Q1 2026 in Review

SageView Advisory Group sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 106 shares — an estimated $9.26K sold.

SageView Advisory Group first reported a position in PTGX in Q4 2025 and held it in 1 quarter. The position peaked at $9.26K in Q4 2025. 320 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • SageView Advisory Group reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 106 Protagonist Therapeutics shares in Q1 2026, an estimated $9.26K.
  • SageView Advisory Group first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Protagonist Therapeutics position peaked at $9.26K in Q4 2025.
  • 320 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.